BioSpace News Archive

- National reimbursement adds the device into Japan’s health insurance system, which enables greater access for patients - MitraClip is a first-of-its-kind transcatheter mitral valve repair device that provides physicians with a minimally invasive way to repair leaky heart valves in people for whom surgery is too risky

President and CEO, Christopher J. Burns, Ph.D., will present at the First-Time Disclosure of Clinical Candidates Oral Symposium on March 21, 2018 at 3:15pm CT

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced UCB has elected to exclusively license an undisclosed drug target for inflammatory diseases.

AMPAC Fine Chemicals (AFC) today announced that Lee Gauthier has joined AFC’s executive team as Vice President of Operations responsible for manufacturing across all AFC’s sites.

Avita Medical announced the commencement of a randomized, controlled clinical trial of RECELL® in the treatment of deep partial-thickness (second-degree) burns in China.

Arena Pharmaceuticals, Inc. announced positive topline Phase 2 results from the OASIS trial for etrasimod.

Proteostasis Therapeutics, Inc. announced today that it intends to offer and sell, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering.

Xencor Inc. announced that it intends to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering.

Veracyte, Inc. announced that its soon-to-be-launched Afirma Xpression Atlas platform was unveiled at ENDO 2018, the annual meeting of the Endocrine Society, being held March 17-20 in Chicago.

Pfizer Inc. and Astellas Pharma, Inc. announced that a supplemental New Drug Application (sNDA) for XTANDI® (enzalutamide) has been accepted for filing and granted Priority Review designation by the U.S. Food and Drug Administration (FDA).